Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Emmessar Biotech And Nutrition Current Ratio?
Emmessar Biotech And NutritionBOM:524768 +1.93%55 Current Ratio is 20.27 as of Mar. 2026, which is 111% above its 10-year median of 9.59. GuruFocus rates BOM:524768 with a GF Score™ of 55/100 and a GF Value™ of ₹18.67 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,000 Drug Manufacturers companies, Emmessar Biotech And Nutrition ranks better than 97.7% on this metric.
Emmessar Biotech And Nutrition has a current ratio of 20.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Emmessar Biotech And Nutrition's Current Ratio or its related term are showing as below:
BOM:524768'
s Current Ratio Range Over the Past 10 Years
Min: 2.67 Med: 9.59 Max: 20.27
Current: 20.27
During the past 13 years, Emmessar Biotech And Nutrition's highest Current Ratio was 20.27. The lowest was 2.67. And the median was 9.59.
BOM:524768's Current Ratio is ranked better than 97.7% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:524768: 20.27
Emmessar Biotech And Nutrition (BOM:524768) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Emmessar Biotech And Nutrition Current Ratio Related Terms
Emmessar Biotech And Nutrition Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmessar Biotech And Nutrition Current Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Emmessar Biotech And Nutrition's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmessar Biotech And Nutrition Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emmessar Biotech And Nutrition's Current Ratio distribution charts can be found below:
* The bar in red indicates where Emmessar Biotech And Nutrition's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmessar Biotech And Nutrition (BOM:524768) has a Current Ratio of 20.27 as of Mar. 2026. This is 111% above median its historical median of 9.59. Over the past decade, Emmessar Biotech And Nutrition's Current Ratio has ranged from 2.67 to 20.27. According to the industry distribution chart, Emmessar Biotech And Nutrition ranks #23 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is Emmessar Biotech And Nutrition's Current Ratio too high?
Emmessar Biotech And Nutrition's current Current Ratio of 20.27 is 111% above median its 10-year median of 9.59. Over the past 10 years, this metric has ranged from a low of 2.67 to a high of 20.27. The Drug Manufacturers industry median Current Ratio is 1.97. Emmessar Biotech And Nutrition's value of 20.27 is 928.9% above this industry median. Based on the distribution chart, Emmessar Biotech And Nutrition ranks #23 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Emmessar Biotech And Nutrition has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emmessar Biotech And Nutrition's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emmessar Biotech And Nutrition ranks #23 out of 1000 companies for Current Ratio. This places Emmessar Biotech And Nutrition in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.97. Emmessar Biotech And Nutrition's value of 20.27 is 928.9% above this benchmark. Historically, Emmessar Biotech And Nutrition's own Current Ratio has ranged from 2.67 to 20.27 over the past decade. While the company's 10-year median is 9.59 vs. the industry median of 1.97, Emmessar Biotech And Nutrition has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.97, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmessar Biotech And Nutrition's current Current Ratio of 20.27 is 928.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmessar Biotech And Nutrition's current Current Ratio is 20.27, which is 111% above median its own 10-year median of 9.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmessar Biotech And Nutrition stock overvalued right now?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition (BOM:524768) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.67, compared to a current price of ₹25.34 — trading 35.7% above its estimated fair value. The current Current Ratio is 20.27, which is 111% above median its 10-year median of 9.59 and 928.9% above the Drug Manufacturers industry median of 1.97. Emmessar Biotech And Nutrition's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Emmessar Biotech And Nutrition (BOM:524768), the current Current Ratio is 20.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emmessar Biotech And Nutrition (BOM:524768) Overvalued in 2026?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition stock appears to be overvalued.
The current stock price of ₹25.34 is trading 35.7% above its estimated GF Value™ of ₹18.67.
GuruFocus considers Emmessar Biotech And Nutrition to be Significantly Overvalued.
Key valuation signals for BOM:524768:
Current Ratio: 20.27 (111% above median its 10-year median of 9.59)
GF Value™: ₹18.67 vs. price of ₹25.34 (35.7% above fair value)
Industry Position: 928.9% above the Drug Manufacturers median (#23 of 1000)
No single metric tells the full story. See the BOM:524768 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emmessar Biotech And Nutrition Ltd is a healthcare company. The company is engaged in the manufacturing and marketing of fine chemicals products, and healthcare and nutritional products. The company caters to patients with obstinate skin problems, muscle problems, bone problems, and other debilitating chronic physical ailments. The business segments of the company are Healthcare, Fine Chemicals, and Rent on Immovable property of which the majority of the revenue is derived from the Rent on Lease land segment.
55GF Score
Get the complete analysis for BOM:524768
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524768 has been successfully added to your 
